{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["30(5)"],"submitter":["Unseld M"],"pubmed_abstract":["Objective
Advances in high-throughput genomic profiling and the development of new targeted therapies improve patient's survival. In gastrointestinal (GI) malignancies, the concept of personalized medicine (PM) was not investigated so far. The aim of this prospective study was to evaluate the efficacy of a personalized treatment in GI patients who failed standard treatment.Methods
Out of the original prospective clinical phase II EXACT trial, 21 (38%) GI cancer patients who had no further treatment options were identified. A molecular profile (MP) via a 50 gene next generation sequencing (NGS) panel in combination with immunohistochemistry (IHC) was conducted using real-time biopsy tumor material. Results were discussed by a multidisciplinary team (MDT) to translate the ind"],"journal":["Chinese journal of cancer research = Chung-kuo yen cheng yen chiu"],"pagination":["508-515"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6232366"],"repository":["biostudies-literature"],"pubmed_title":["Feasibility of personalized treatment concepts in gastrointestinal malignancies: Sub-group results of prospective clinical phase II trial EXACT."],"pmcid":["PMC6232366"],"pubmed_authors":["Unseld M","Bianconi D","Wrba F","Sibilia M","Baumann L","Prager GW","Mullauer L","Veraar C","Zielinski C","Mader R","Waneck F","Berger W","Kieler M"],"additional_accession":[]},"is_claimable":false,"name":"Feasibility of personalized treatment concepts in gastrointestinal malignancies: Sub-group results of prospective clinical phase II trial EXACT.","description":"Objective
Advances in high-throughput genomic profiling and the development of new targeted therapies improve patient's survival. In gastrointestinal (GI) malignancies, the concept of personalized medicine (PM) was not investigated so far. The aim of this prospective study was to evaluate the efficacy of a personalized treatment in GI patients who failed standard treatment.Methods
Out of the original prospective clinical phase II EXACT trial, 21 (38%) GI cancer patients who had no further treatment options were identified. A molecular profile (MP) via a 50 gene next generation sequencing (NGS) panel in combination with immunohistochemistry (IHC) was conducted using real-time biopsy tumor material. Results were discussed by a multidisciplinary team (MDT) to translate the ind","dates":{"release":"2018-01-01T00:00:00Z","publication":"2018 Oct","modification":"2025-04-22T15:26:51.607Z","creation":"2019-03-27T00:10:55Z"},"accession":"S-EPMC6232366","cross_references":{"pubmed":["30510362"],"doi":["10.21147/j.issn.1000-9604.2018.05.04"]}}